SEC Form 4 · accession 0001214659-17-006089
NEXIEN BIOPHARMA, INC. · NXEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard S Greenberg
Officer — EVP and Chairman · Director · 10% Owner
Period of report
Oct 13, 2017
Accepted (ET)
Oct 18, 2017 · 11:28 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001625288
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 13, 2017 | J | 20,000,000 | — | D | 0 | I | By Intiva USA Inc. |
| Common StockF2 | Oct 13, 2017 | J | 53,405,501 | — | A | 53,405,501 | I | By Intiva USA Inc. |
| Common StockF3 | Oct 13, 2017 | J | 1,780,183 | — | A | 1,780,183 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Surrendered as part of share exchange transaction
- F2Acquired in exchange for all of Intiva USA's shares of Intiva BioPharma Inc.
- F3Acquired in exchange for all of Richard Greenberg's shares of Intiva BioPharma Inc.